---
document_datetime: 2025-12-02 05:35:01
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/duvyzat.html
document_name: duvyzat.html
version: success
processing_time: 0.106557
conversion_datetime: 2025-12-27 18:23:48.31019
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Duvyzat

[RSS](/en/individual-human-medicine.xml/256950)

##### Authorised

This medicine is authorised for use in the European Union

givinostat Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Duvyzat](#news-on)
- [More information on Duvyzat](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Duvyzat is a medicine used to treat people aged 6 years and older with Duchenne muscular dystrophy who are able to walk and are already being treated with corticosteroids. Duchenne muscular dystrophy is a genetic disease that gradually causes weakness and loss of muscle function.

Duchenne muscular distrophy is rare, and Duvyzat was designated an 'orphan medicine' (a medicine used in rare diseases) on 4 July 2012. Further information on the orphan designation can be found on the EMA [website](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1009) .

Duvyzat contains the active substance givinostat.

Expand section

Collapse section

## How is Duvyzat used?

Duvyzat can only be obtained with a prescription and should be prescribed by a doctor experienced in treating patients with Duchenne muscular dystrophy.

Duvyzat is available as a liquid to be taken by mouth with food twice a day. Before starting treatment with Duvyzat, doctors will ensure that patients have normal platelet levels (platelets are components that help the blood to clot). During treatment, platelet and triglyceride levels should be monitored regularly and the dose of Duvyzat may need to be adjusted based on the results. In patients who get diarrhoea (more than 4 stools a day) during treatment, the dose of Duvyzat may also need to be adjusted.

For more information about using Duvyzat, see the package leaflet or contact your doctor or pharmacist.

## How does Duvyzat work?

The active substance in Duvyzat, givinostat, blocks the activity of certain enzymes called histone deacetylases (HDAC), which control how genes are read and used to make proteins, including those involved in muscle repair.

It is thought that dystrophic muscle cells have increased HDAC activity, which reduces the production of proteins that repair muscles, leading to inflammation, scarring and thickening, and fat build-up in muscles.

By blocking HDAC activity, givinostat helps restore the production of proteins involved in muscle repair, reducing muscle damage and helping to slow the progression of the disease.

## What benefits of Duvyzat have been shown in studies?

In a main study in boys aged 6 years and older with Duchenne muscular dystrophy who were able to walk and were being treated with corticosteroids, Duvyzat was shown to slow the decline in patients' ability to walk.

In the study, 81 boys received Duvyzat and 39 received placebo (a dummy treatment), both in addition to corticosteroids. The main measure of effectiveness was the change in patients' ability to walk, measured by the time needed to climb 4 steps.

After 18 months of treatment, patients taking Duvyzat took an average of 1.25 seconds longer to climb four steps. Those given placebo had a greater increase, taking 3.03 seconds longer on average.

## What are the risks associated with Duvyzat?

For the full list of side effects and restrictions with Duvyzat, see the package leaflet.

The most common side effects with Duvyzat (which may affect more than 1 in 10 people) include diarrhoea, abdominal (belly) pain, thrombocytopenia (low levels of blood platelets), vomiting and hypertriglyceridaemia (high blood levels of triglycerides, a type of fat).

## Why is Duvyzat authorised in the EU?

At the time of authorisation, corticosteroids were the only medicines used for the treatment of Duchenne muscular dystrophy. Based on the study results, Duvyzat is expected to slow the progression of the disease, especially when started early. However, there were uncertainties regarding the magnitude of Duvyzat's effect and the European Medicines Agency therefore requested that further studies be conducted to confirm the medicine's effectiveness. The side effects with Duvyzat were mostly mild to moderate and considered manageable. The European Medicines Agency therefore decided that Duvyzat's benefits are greater than its risks and it can be authorised for use in the EU.

Duvyzat has been given conditional authorisation. This means that it has been authorised on the basis of less comprehensive data than are normally required because it fulfils an unmet medical need. The Agency considers that the benefit of having the medicine available earlier outweighs any risks associated with using it while awaiting further evidence.

The company must provide further data on Duvyzat. It must submit results from two studies to confirm the safety and effectiveness of the medicine, including in the long-term. Every year, the Agency will review any new information that becomes available.

## What measures are being taken to ensure the safe and effective use of Duvyzat?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Duvyzat have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Duvyzat are continuously monitored. Suspected side effects reported with Duvyzat are carefully evaluated and any necessary action taken to protect patients.

## Other information about Duvyzat

Duvyzat received a conditional marketing authorisation valid throughout the EU on 6 June 2025

Duvyzat : EPAR - Medicine overview

Reference Number: EMA/155565/2025

English (EN) (112.47 KB - PDF)

**First published:** 09/07/2025

[View](/en/documents/overview/duvyzat-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-340)

български (BG) (135.89 KB - PDF)

**First published:**

09/07/2025

[View](/bg/documents/overview/duvyzat-epar-medicine-overview_bg.pdf)

español (ES) (110.91 KB - PDF)

**First published:**

09/07/2025

[View](/es/documents/overview/duvyzat-epar-medicine-overview_es.pdf)

čeština (CS) (133.84 KB - PDF)

**First published:**

09/07/2025

[View](/cs/documents/overview/duvyzat-epar-medicine-overview_cs.pdf)

dansk (DA) (111.78 KB - PDF)

**First published:**

09/07/2025

[View](/da/documents/overview/duvyzat-epar-medicine-overview_da.pdf)

Deutsch (DE) (114.38 KB - PDF)

**First published:**

09/07/2025

[View](/de/documents/overview/duvyzat-epar-medicine-overview_de.pdf)

eesti keel (ET) (108.75 KB - PDF)

**First published:**

09/07/2025

[View](/et/documents/overview/duvyzat-epar-medicine-overview_et.pdf)

ελληνικά (EL) (134.8 KB - PDF)

**First published:**

09/07/2025

[View](/el/documents/overview/duvyzat-epar-medicine-overview_el.pdf)

français (FR) (112.24 KB - PDF)

**First published:**

09/07/2025

[View](/fr/documents/overview/duvyzat-epar-medicine-overview_fr.pdf)

hrvatski (HR) (133.42 KB - PDF)

**First published:**

09/07/2025

[View](/hr/documents/overview/duvyzat-epar-medicine-overview_hr.pdf)

italiano (IT) (110.45 KB - PDF)

**First published:**

09/07/2025

[View](/it/documents/overview/duvyzat-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (140.54 KB - PDF)

**First published:**

09/07/2025

[View](/lv/documents/overview/duvyzat-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (132.9 KB - PDF)

**First published:**

09/07/2025

[View](/lt/documents/overview/duvyzat-epar-medicine-overview_lt.pdf)

magyar (HU) (134.23 KB - PDF)

**First published:**

09/07/2025

[View](/hu/documents/overview/duvyzat-epar-medicine-overview_hu.pdf)

Malti (MT) (135.03 KB - PDF)

**First published:**

09/07/2025

[View](/mt/documents/overview/duvyzat-epar-medicine-overview_mt.pdf)

Nederlands (NL) (112.41 KB - PDF)

**First published:**

09/07/2025

[View](/nl/documents/overview/duvyzat-epar-medicine-overview_nl.pdf)

polski (PL) (139.18 KB - PDF)

**First published:**

09/07/2025

[View](/pl/documents/overview/duvyzat-epar-medicine-overview_pl.pdf)

português (PT) (111.72 KB - PDF)

**First published:**

09/07/2025

[View](/pt/documents/overview/duvyzat-epar-medicine-overview_pt.pdf)

română (RO) (130.1 KB - PDF)

**First published:**

09/07/2025

[View](/ro/documents/overview/duvyzat-epar-medicine-overview_ro.pdf)

slovenčina (SK) (132.86 KB - PDF)

**First published:**

09/07/2025

[View](/sk/documents/overview/duvyzat-epar-medicine-overview_sk.pdf)

slovenščina (SL) (130.58 KB - PDF)

**First published:**

09/07/2025

[View](/sl/documents/overview/duvyzat-epar-medicine-overview_sl.pdf)

Suomi (FI) (109.16 KB - PDF)

**First published:**

09/07/2025

[View](/fi/documents/overview/duvyzat-epar-medicine-overview_fi.pdf)

svenska (SV) (110.11 KB - PDF)

**First published:**

09/07/2025

[View](/sv/documents/overview/duvyzat-epar-medicine-overview_sv.pdf)

Duvyzat : EPAR - Risk management plan

English (EN) (440.74 KB - PDF)

**First published:** 09/07/2025

[View](/en/documents/rmp/duvyzat-epar-risk-management-plan_en.pdf)

## Product information

Duvyzat : EPAR - Product information

English (EN) (624.4 KB - PDF)

**First published:** 09/07/2025

**Last updated:** 27/10/2025

[View](/en/documents/product-information/duvyzat-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-633)

български (BG) (755.6 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/bg/documents/product-information/duvyzat-epar-product-information_bg.pdf)

español (ES) (645.39 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/es/documents/product-information/duvyzat-epar-product-information_es.pdf)

čeština (CS) (746.68 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/cs/documents/product-information/duvyzat-epar-product-information_cs.pdf)

dansk (DA) (673.65 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/da/documents/product-information/duvyzat-epar-product-information_da.pdf)

Deutsch (DE) (696.18 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/de/documents/product-information/duvyzat-epar-product-information_de.pdf)

eesti keel (ET) (669.01 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/et/documents/product-information/duvyzat-epar-product-information_et.pdf)

ελληνικά (EL) (716.03 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/el/documents/product-information/duvyzat-epar-product-information_el.pdf)

français (FR) (725.55 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/fr/documents/product-information/duvyzat-epar-product-information_fr.pdf)

hrvatski (HR) (787.39 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/hr/documents/product-information/duvyzat-epar-product-information_hr.pdf)

íslenska (IS) (608.55 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/is/documents/product-information/duvyzat-epar-product-information_is.pdf)

italiano (IT) (695.58 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/it/documents/product-information/duvyzat-epar-product-information_it.pdf)

latviešu valoda (LV) (715.64 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/lv/documents/product-information/duvyzat-epar-product-information_lv.pdf)

lietuvių kalba (LT) (697.52 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/lt/documents/product-information/duvyzat-epar-product-information_lt.pdf)

magyar (HU) (758.16 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/hu/documents/product-information/duvyzat-epar-product-information_hu.pdf)

Malti (MT) (717.2 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/mt/documents/product-information/duvyzat-epar-product-information_mt.pdf)

Nederlands (NL) (693.77 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/nl/documents/product-information/duvyzat-epar-product-information_nl.pdf)

norsk (NO) (628.3 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/no/documents/product-information/duvyzat-epar-product-information_no.pdf)

polski (PL) (732.61 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/pl/documents/product-information/duvyzat-epar-product-information_pl.pdf)

português (PT) (672.8 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/pt/documents/product-information/duvyzat-epar-product-information_pt.pdf)

română (RO) (747.98 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/ro/documents/product-information/duvyzat-epar-product-information_ro.pdf)

slovenčina (SK) (744.92 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/sk/documents/product-information/duvyzat-epar-product-information_sk.pdf)

slovenščina (SL) (766.16 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/sl/documents/product-information/duvyzat-epar-product-information_sl.pdf)

Suomi (FI) (675.78 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/fi/documents/product-information/duvyzat-epar-product-information_fi.pdf)

svenska (SV) (608.09 KB - PDF)

**First published:**

09/07/2025

**Last updated:**

27/10/2025

[View](/sv/documents/product-information/duvyzat-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000282569 17/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Duvyzat : EPAR - All authorised presentations

English (EN) (44.5 KB - PDF)

**First published:** 09/07/2025

[View](/en/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-928)

български (BG) (53.02 KB - PDF)

**First published:**

09/07/2025

[View](/bg/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_bg.pdf)

español (ES) (45.92 KB - PDF)

**First published:**

09/07/2025

[View](/es/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_es.pdf)

čeština (CS) (53.16 KB - PDF)

**First published:**

09/07/2025

[View](/cs/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (37.99 KB - PDF)

**First published:**

09/07/2025

[View](/da/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (37.84 KB - PDF)

**First published:**

09/07/2025

[View](/de/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (43.64 KB - PDF)

**First published:**

09/07/2025

[View](/et/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (48.43 KB - PDF)

**First published:**

09/07/2025

[View](/el/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_el.pdf)

français (FR) (45.33 KB - PDF)

**First published:**

09/07/2025

[View](/fr/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (83.38 KB - PDF)

**First published:**

09/07/2025

[View](/hr/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (47.18 KB - PDF)

**First published:**

09/07/2025

[View](/is/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_is.pdf)

italiano (IT) (45.17 KB - PDF)

**First published:**

09/07/2025

[View](/it/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (46.25 KB - PDF)

**First published:**

09/07/2025

[View](/lv/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (46.43 KB - PDF)

**First published:**

09/07/2025

[View](/lt/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (71.42 KB - PDF)

**First published:**

09/07/2025

[View](/hu/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (51.61 KB - PDF)

**First published:**

09/07/2025

[View](/mt/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (44.69 KB - PDF)

**First published:**

09/07/2025

[View](/nl/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (47.54 KB - PDF)

**First published:**

09/07/2025

[View](/no/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_no.pdf)

polski (PL) (46.74 KB - PDF)

**First published:**

09/07/2025

[View](/pl/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_pl.pdf)

português (PT) (46.25 KB - PDF)

**First published:**

09/07/2025

[View](/pt/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_pt.pdf)

română (RO) (45.68 KB - PDF)

**First published:**

09/07/2025

[View](/ro/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (47.88 KB - PDF)

**First published:**

09/07/2025

[View](/sk/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (43.81 KB - PDF)

**First published:**

09/07/2025

[View](/sl/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (43.99 KB - PDF)

**First published:**

09/07/2025

[View](/fi/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (47.3 KB - PDF)

**First published:**

09/07/2025

[View](/sv/documents/all-authorised-presentations/duvyzat-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Duvyzat Active substance givinostat hydrochloride monohydrate International non-proprietary name (INN) or common name givinostat Therapeutic area (MeSH) Muscular Dystrophy, Duchenne Anatomical therapeutic chemical (ATC) code M09AX14

### Pharmacotherapeutic group

Other drugs for disorders of the musculo-skeletal system

### Therapeutic indication

Duvyzat is indicated for the treatment of Duchenne muscular dystrophy (DMD) in ambulant patients, aged 6 years and older, and with concomitant corticosteroid treatment.

## Authorisation details

EMA product number EMEA/H/C/006079

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Italfarmaco S.p.A.

Viale Fulvio Testi 330 20126 Milan Italy

Opinion adopted 25/04/2025 Marketing authorisation issued 06/06/2025 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Duvyzat : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (175.39 KB - PDF)

**First published:** 18/07/2025

[View](/en/documents/procedural-steps-after/duvyzat-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Duvyzat : Orphan maintenance assessment report (initial-authorisation)

Adopted

Reference Number: EMADOC-1700519818-2104019

English (EN) (353.78 KB - PDF)

**First published:** 09/07/2025

[View](/en/documents/orphan-maintenance-report/duvyzat-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Duvyzat : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/176222/2025

English (EN) (4.18 MB - PDF)

**First published:** 09/07/2025

[View](/en/documents/assessment-report/duvyzat-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Duvyzat

Adopted

Reference Number: EMA/CHMP/90149/2025

English (EN) (154.84 KB - PDF)

**First published:** 25/04/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-duvyzat_en.pdf)

#### News on Duvyzat

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2025) 25/04/2025

[New treatment against Duchenne muscular dystrophy](/en/news/new-treatment-against-duchenne-muscular-dystrophy) 25/04/2025

#### More information on Duvyzat

- [EU/3/12/1009 - orphan designation for treatment of Duchenne muscular dystrophy](/en/medicines/human/orphan-designations/eu-3-12-1009)

**This page was last updated on** 18/07/2025

## Share this page

[Back to top](#main-content)